TY - JOUR
T1 - Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana
T2 - a cross-sectional study
AU - Mwita, Julius Chacha
AU - Francis, Joel M.
AU - Omech, Bernard
AU - Botsile, Elizabeth
AU - Oyewo, Aderonke
AU - Mokgwathi, Matshidiso
AU - Molefe-Baikai, Onkabetse Julia
AU - Godman, Brian
AU - Tshikuka, Jose Gaby
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2019.
PY - 2019
Y1 - 2019
N2 - Objective Control of glycaemic, hypertension and low-density lipoprotein-cholesterol (LDL-C) among patients with type 2 diabetes mellitus (T2DM) is vital for the prevention of cardiovascular diseases. The current study was an audit of glycaemic, hypertension and LDL-C control among ambulant patients with T2DM in Botswana. Also, the study aimed at assessing factors associated with attaining optimal glycaemic, hypertension and LDL-C therapeutic goals. Design A cross-sectional study. setting A specialised public diabetes clinic in Gaborone, Botswana. Participants Patients with T2DM who had attended the clinic for ≥3 months between August 2017 and February 2018. Primary outcome measure The proportion of patients with optimal glycaemic (HbA1c<7%), hypertension (blood pressure <140/90 mm Hg) and LDL-C (<1.8 mmol/L) control. results The proportions of patients meeting optimal targets were 32.3% for glycaemic, 54.2% for hypertension and 20.4% for LDL-C. Age≥ 50 years was positively associated with optimal glycaemic control (adjusted OR [AOR] 5.79; 95% CI 1.08 to 31.14). On the other hand, an increase in diabetes duration was inversely associated with optimal glycemic control (AOR 0.91; 95% CI 0.85 to 0.98). Being on an ACE inhibitor was inversely associated with optimal hypertension control (AOR 0.35; 95% CI 0.14 to 0.85). Being female was inversely associated with optimal LDL-C control (AOR 0.24; 95% CI (0.09 - 0.59). Conclusion Patients with T2DM in Gaborone, Botswana, presented with suboptimal control of recommended glycaemic, hypertension and LDL-C targets. These findings call for urgent individual and health systems interventions to address key determinants of the recommended therapeutic targets among patients with diabetes in this setting.
AB - Objective Control of glycaemic, hypertension and low-density lipoprotein-cholesterol (LDL-C) among patients with type 2 diabetes mellitus (T2DM) is vital for the prevention of cardiovascular diseases. The current study was an audit of glycaemic, hypertension and LDL-C control among ambulant patients with T2DM in Botswana. Also, the study aimed at assessing factors associated with attaining optimal glycaemic, hypertension and LDL-C therapeutic goals. Design A cross-sectional study. setting A specialised public diabetes clinic in Gaborone, Botswana. Participants Patients with T2DM who had attended the clinic for ≥3 months between August 2017 and February 2018. Primary outcome measure The proportion of patients with optimal glycaemic (HbA1c<7%), hypertension (blood pressure <140/90 mm Hg) and LDL-C (<1.8 mmol/L) control. results The proportions of patients meeting optimal targets were 32.3% for glycaemic, 54.2% for hypertension and 20.4% for LDL-C. Age≥ 50 years was positively associated with optimal glycaemic control (adjusted OR [AOR] 5.79; 95% CI 1.08 to 31.14). On the other hand, an increase in diabetes duration was inversely associated with optimal glycemic control (AOR 0.91; 95% CI 0.85 to 0.98). Being on an ACE inhibitor was inversely associated with optimal hypertension control (AOR 0.35; 95% CI 0.14 to 0.85). Being female was inversely associated with optimal LDL-C control (AOR 0.24; 95% CI (0.09 - 0.59). Conclusion Patients with T2DM in Gaborone, Botswana, presented with suboptimal control of recommended glycaemic, hypertension and LDL-C targets. These findings call for urgent individual and health systems interventions to address key determinants of the recommended therapeutic targets among patients with diabetes in this setting.
UR - http://www.scopus.com/inward/record.url?scp=85070513860&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2018-026807
DO - 10.1136/bmjopen-2018-026807
M3 - Article
C2 - 31340960
AN - SCOPUS:85070513860
SN - 2044-6055
VL - 9
JO - BMJ Open
JF - BMJ Open
IS - 7
M1 - e026807
ER -